Interní Med. 2009; 11(7): 319-323

Chronic obstructive pulmonary disease

doc. MUDr. Jaromír Musil CSc
Pneumologická klinika 2. LF UK a FN Motol, Praha

COPD is a treatable disease that can be prevented. COPD has significant extrapulmonary effects that can contribute to the overall severity

of the disease in individual patients. Its pulmonary component is characterized by a limited air flow in the bronchi (hereafter referred

to as bronchial obstruction) which is not fully reversible. Bronchial obstruction usually progresses and is associated with an abnormal

inflammatory response of the lungs to harmful particles and gases. Bronchial obstruction typical for COPD results from a common involvement

of the small airways (obstructive bronchiolitis) and the destruction of lung parenchyma (emphysema). Cigarette smoking is the

major risk factor for developing COPD. Cessation of smoking is essential for treatment. Treatment consists of both short- and long-acting

bronchodilators. Inhaled corticosteroids may be given to reduce the exacerbation rate.

Keywords: chronic obstructive pulmonary disease, diagnosis, treatment.

Published: September 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Musil J. Chronic obstructive pulmonary disease. Interní Med. 2009;11(7):319-323.
Download citation

References

  1. Světová iniciativa o chronické obstrukční plicní nemoci. Světová strategie diagnostiky, léčby a prevence chronické obstrukční plicní nemoci 2006. Překlad Vltavín, Praha 2007; 161 s.
  2. Snider GL, Kleinerman J, Thurlbeck WM, et al. The definition of emphysema: report of a National Heart and Blood Institute, Division of Lung Diseases, workshop. Am. Rev. Resp. Dis 1985; 132: 182-185.
  3. Vondra V. a kolektiv autorů. Péče o nemocné s chronickou obstrukční plicní nemocí v České republice. Jalna, 1996, 160 s.
  4. Rahman I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. Cell Biochem Biophys 2005; 43: 167-188. Go to original source... Go to PubMed...
  5. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001; 429: 195-207. Go to original source... Go to PubMed...
  6. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-1976. Go to original source... Go to PubMed...
  7. Mullen JB., Wright JL, Wiggs BR, et al. Reassessment of inflammation of airways in chronic bronchitis. BMJ (Clin Res Ed) 1985; 291: 1235-1239. Go to original source... Go to PubMed...
  8. Dayman H. Mechanics of airflow in health and emphysema. J Clin Invest 1951; 30: 1175-1190. Go to original source... Go to PubMed...
  9. Yin P, Juan CQ, Cheng KK, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzou Biobank Kohort Study. Lancet 2007; 370: 751-757. Go to original source... Go to PubMed...
  10. Chlumský J, Fišerová J, Satinská J, a kol. Doporučený postup pro interpretaci základních vyšetření plicních funkcí www.pneumologie.cz.
  11. Anthonisen NR, Connet JE, Kiley JP, et al. Effects of smoking intervention and the use of inhaled anticholinergic bronchodilatator on the rate of decline of FEV1: The Lung Health Study. JAMA 1994; 272: 1497-1505. Go to original source...
  12. Sinclair HK, Bond CM, Stead LF. Community pharmacy personnel interventions for smoking cessation. Cochrane Databaze Syst Rev 2004; 1: CD000214. Go to original source... Go to PubMed...
  13. Tashkin DP, Celli B, Senn S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. NEJM 2008; 359: 1543-1554. Go to original source... Go to PubMed...
  14. Koblížek V. Studie UPLIFT- vliv dlouhodobého podávání tiotropia na plicní funkce u pacientů s chronickou obstrukční plicní nemocí. Remedia 2009; 19: 59-62.
  15. Pieper MP, Chaudhary NI, Park JE. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide. Life Science 2007; 80: 3200-3205. Go to original source... Go to PubMed...
  16. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta agonists in stable COPD: A systematic review. Chest 2008; 133: 1079-1089. Go to original source... Go to PubMed...
  17. Cyr MC, Beauchesne MF, Lemiere C, et al. Effects of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology 2008; 65: 40-50. Go to original source... Go to PubMed...
  18. Keatings MV, Jakaton A, Worsdell YM. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-548. Go to original source... Go to PubMed...
  19. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391-398. Go to original source... Go to PubMed...
  20. Česká pneumologická a phtizeologická společnost. Terapie kyslíkem v domácím prostředí - DDOT (dlouhodobá domácí oxygenoterapie) www.pneumologie.cz.
  21. Hosenpud, JD, Bennett LE, Keck BM, et al. The registry of the International Society for Heart and Lung Transplantation: fifteenth official report - 1998. J Heart Lung Transplant 1998; 17: 656-668.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.